CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy

Post time 4 hour(s) ago

journal：New England Journal of Medicine

Authors：Marianna Fontana; Scott D. Solomon; Jessica Kachadourian; Liron Walsh; Ricardo Rocha; David Lebwohl; Derek Smith; Jrg Tubel; Edward J. Gane; Bjrn Pilebro; David Adams; Yousuf Razvi; Joy Olbertz; Alexandra Haagensen; Peijuan Zhu; Yuanxin Xu; Adia Leung; Alison Sonderfan; David E. Gutstein; Julian D. Gillmore

Published date：2024-12-12

DOI：10.1056/nejmoa2412309

PDF link：http://www.nejm.org/doi/pdf/10.1056/NEJMoa2412309

Article link：https://doi.org/10.1056/nejmoa2412309

Article Source：Massachusetts Medical Society。

Remark：

Post time 4 hour(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[NEJM] CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy